Previous 10 | Next 10 |
Sunworks (SUNW) +355%.Polar Power (POLA) +88%.The E.W. Scripps Company (SSP) +68% on ION Media acquisition.SPI Energy (SPI) +51%.LogicBio Therapeutics (LOGC) +45%.Owens & Minor (OMI) +28% after raising full-year guidance.Electrameccanica Vehicles (SOLO) +16% ...
USFDA granted Leap Therapeutics (LPTX) +8.8% fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express high Dickkopf-1 protein (DKK1), following disease progression on or after prior fluoropy...
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer PR Newswire CAMBRIDGE, Mass., Sept. 24, 2020 CAMBRIDGE, Mass. , Sept. 24, 2020 /PRNewswire/ -- Leap Therapeutics...
Leap Therapeutics (LPTX) up 7.2% in premarket, and BeiGene, (BGNE) have announced that first patient has been dosed in the DisTinGuish Phase 2a trial, evaluating Leap's DKN-01, in combination with latter's tislelizumab, with or without chemotherapy in patients with gastric...
Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer PR Newswire CAMBRIDGE, Mass. and BEIJING, Sept. 21, 2020 CAMBRIDGE, Mass. an...
Leap Therapeutics (NASDAQ: LPTX ) has filed a preliminary prospectus for a $150 mixed shelf offering. More news on: Leap Therapeutics, Inc., Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass. , Sept. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi , President and Chief Executive Officer, will present a corporate ove...
A Penny Stocks List For September Should your list of penny stocks include hundreds of names? Honestly, when you’re putting together a watch list, you should keep a few things in mind. First, buying shares of every stock on that list isn’t efficient. You want to stay focused. F...
CAMBRIDGE, Mass. , Aug. 24, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the expansion of its leadership team with the appointment of Jason S. Baum , Ph.D., as Vice Pr...
Leap Therapeutics (NASDAQ: LPTX ) : Q2 GAAP EPS of -$0.12 beats by $0.06 . More news on: Leap Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today report...
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...